Twist Bioscience (TWST) Common Equity (2017 - 2026)

Twist Bioscience (TWST) has reported Common Equity for 10 consecutive years, with $455.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity rose 3.41% year-over-year to $455.1 million; the TTM figure through Mar 2026 stood at $455.1 million (up 3.41% YoY), while the FY2025 annual figure was $473.0 million, changed 0.06% from the prior year.
• Common Equity was little changed at $455.1 million in Q1 2026 per TWST's latest filing, from $456.1 million in the prior quarter.
• Across five years, Common Equity topped out at $863.4 million in Q1 2022 and bottomed at $440.1 million in Q1 2025.
• Historically, Common Equity has averaged $592.8 million across 5 years, with a median of $560.1 million in 2024.
• Annual changes were most pronounced in 2022 — Common Equity soared 40.57% — and 2024, when it slipped 25.31%.
• Twist Bioscience's Common Equity stood at $746.3 million in 2022, then retreated by 20.94% to $590.0 million in 2023, then fell by 22.73% to $455.9 million in 2024, then climbed by 0.03% to $456.1 million in 2025, then dropped by 0.22% to $455.1 million in 2026.
• Business Quant data shows TWST's Common Equity at $455.1 million in Q1 2026, $456.1 million in Q4 2025, and $473.0 million in Q3 2025.